The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate Pharmaceuticals. Dr. Osei Tutu brings valuable regulatory experience in the immune-oncology landscape to the team at Checkmate as they keep their focus on important regulatory milestones for vidutolimod. This hands-on role gives Dr. Osei Tutu responsibility for the development and execution of Checkmate’s global regulatory strategy as the team’s regulatory expert. Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate is investigating their lead candidate, vidutolimod, across multiple tumor types in combination with checkpoint inhibitor immunotherapies in melanoma and non-melanoma skin cancers and head and neck cancer. A growing body of promising clinical data demonstrates its potential to address the unmet need for patients whose cancers are resistant to immunotherapeutic agents. Dr. Osei Tutu joins a team of scientists, physicians, and life sciences entrepreneurs who are dedicated to discovering and developing new approaches to fighting cancer. The Chase Group is proud to partner with Checkmate and contribute to their success as they work to harness the power of the immune system to combat cancer. For more information on partnering with The Chase Group to identify & secure executive leadership for your organization contact moira@chasegroup.com
The Chase Group Secures VP, Head of Regulatory Affairs for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate Pharmaceuticals. Dr. Osei Tutu brings valuable regulatory experience in the immune-oncology landscape to the team at Checkmate as they keep their focus on important regulatory milestones for vidutolimod. This hands-on role gives Dr. Osei Tutu responsibility for the development and execution of Checkmate’s global regulatory strategy as the team’s regulatory expert. Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate is investigating their lead candidate, vidutolimod, across multiple tumor types in combination with checkpoint inhibitor immunotherapies in melanoma and non-melanoma skin cancers and head and neck cancer. A growing body of promising clinical data demonstrates its potential to address the unmet need for patients whose cancers are resistant to immunotherapeutic agents. Dr. Osei Tutu joins a team of scientists, physicians, and life sciences entrepreneurs who are dedicated to discovering and developing new approaches to fighting cancer. The Chase Group is proud to partner with Checkmate and contribute to their success as they work to harness the power of the immune system to combat cancer. For more information on partnering with The Chase Group to identify & secure executive leadership for your organization contact moira@chasegroup.com- Categories: Life Sciences
The Chase Group Secures VP, Head of Regulatory Affairs for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Teng Jin Ong for Genmab
Amid an era of rapid growth, Genmab retained The Chase Group to secure a new clinical development medical executive as they work to pioneer the…
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…
Arcturus Therapeutics Secures Head of Drug Safety Through Continued Partnership with The Chase Group
The Chase Group’s track record for success continues with another executive placement secured for Arcturus Therapeutics. Entering a new stage in clinical development, Arcturus retained…
Leadership Team Grows at Biologics Consulting Through Partnership with The Chase Group
Biologics Consulting, currently experiencing a season of growth, retained The Chase to build out their leadership team. Tasked with identifying a Regulatory Project Management Lead,…-
The Chase Group Successfully Completes Search for Vice President, Research & Development at Alexza Pharmaceuticals
Alexza Pharmaceuticals stands at the crossroads of innovation and advanced technology with a platform that has the potential to address unmet medical needs in neuroscience….